Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Technology and Oncology Podcast Powered by Carevive

The OCM (Oncology Care Model), launched in 2016, is a payment model designed to help oncology centers transition from the traditional Medicare Fee-for-Service (FFS) payment structure and focus on high-value care. The EOM (Enhancing Oncology Model) is the next phase model and will replace OCM starting July 1, 2023. EOM will support clinicians caring for…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Technology and Oncology Podcast Powered by Carevive

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The OCM (Oncology Care Model), launched in 2016, is a payment model designed to help oncology centers transition from the traditional Medicare Fee-for-Service (FFS) payment structure and focus on high-value care.

The EOM (Enhancing Oncology Model) is the next phase model and will replace OCM starting July 1, 2023. EOM will support clinicians caring for patients with seven common cancer types, focusing on health equity and accountable, affordable care.

But what are the revenue-enhancing opportunities in EOM, is it worth the transition from OCM, and what does it actually provide?

On today’s episode of Technology and Oncology Podcast, host Michelle Dawn Mooney speaks with John Elliot, the Vice President of Sales at Carevive to discuss how oncology centers and clinics can transition from OCM to EOM and how they can get assistance for the process.

Michelle Dawn Mooney and John Elliot discussed:

  1. What clients should expect after approval and assistance available to meet the July 1 deadline for launching
  2. Benefits of EOM to oncology patients
  3. Where people can find more information and assistance on the topic

“Looking at oncology, efficiency is key, however, there are limited constrained resources. 24/7 access to electronic records, having a line of communication, capturing symptoms at the right time, access to care with the focus of addressing challenges in the oncology and health care sector which can improve patient outcome and reduce cost – this is what the EOM aims to achieve. The EOM model bridges the gap of communication and ensures members of the care team are aware of what is happening in real-time, which promotes standardization of care,” explained John Elliot.

John Elliot is the Vice President of Sales at Carevive. He received his Bachelor of Arts degree in Advertising from Southern Methodist University and his Master of Business Administration from Washington University in St. Louis-Olin Business School. He has over ten years of experience working with oncology centers.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512